Company intelligence / Profile preview
Generium
Volginskiy, Vladimirskaya oblast, Russiagenerium.ru ↗
- Ownership
- Private
- Employees
- ~1700
- Development stage
- Other
01
Overview
Generium leads the Russian orphan pharmaceutical market with several biotechnological drugs for rare diseases already approved or in late-stage development. The company has launched biosimilars such as Genolar and supplies products internationally. It maintains high standards of quality control throughout R&D and production processes[1][4][7].
- Therapeutic areas
- OphthalmologyOncologyImmunologyRare Diseases
- Modalities
- Monoclonal antibodies (mAbs)Gene therapyBiosimilarsRecombinant proteins[1][5]
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Selexis SA – partnership for biosimilar development including Genolar® launch in Russia [4]
Beyond the preview
Go deeper on Generium.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Generium.